Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024

May 1, 2024

https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-first-quarter-2024-financial-results-and-provide-a-corporate-update-on-may-7-2024-302133537.html

Conference call and webcast to be held at 4:30 p.m. ET

NEW HAVEN, Conn., May 1, 2024 /PRNewswire/ — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 7, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company’s financial results for the quarter ended March 31, 2024.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.